2018
Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis
Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM, Swisher-McClure S, Kobie J, Moore RD, Rabkin CS, Silverberg MJ, Salters K, Mathews WC, Gill MJ, Thorne JE, Castilho J, Kitahata MM, Justice A, Horberg MA, Achenbach CJ, Mayor AM, Althoff KN. Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 421-429. PMID: 30211722, PMCID: PMC6203623, DOI: 10.1097/qai.0000000000001842.Peer-Reviewed Original ResearchConceptsLung cancer diagnosisCancer diagnosisLung cancerCancer stageNorth American AIDS Cohort CollaborationAdjusted mortality rate ratioHodgkin lymphoma diagnosisOnly lung cancerRole of HIVRisk of deathMortality rate ratiosCohort CollaborationImmune dysfunctionCervical cancerImmune suppressionCancer outcomesSignificant immunosuppressionCancer survivalPoor survivalLymphoma diagnosisMortality rateProbability of survivalPWHHigh mortalityCancer
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeterans
2016
The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality. Journal Of Addiction Medicine 2016, 10: 418-428. PMID: 27610580, PMCID: PMC5083184, DOI: 10.1097/adm.0000000000000255.Peer-Reviewed Original ResearchConceptsSubstance use disordersLong-term opioid therapyCause mortalityOpioid therapySUD treatmentUse disordersLower mortalityTime-updated Cox regressionUntreated substance use disordersVeterans Aging Cohort StudyOpioid-prescribing guidelinesGuideline-concordant careSUD statusAging Cohort StudyClinical practice guidelinesSUD treatment servicesOverall sampleHIV patientsCohort studyCox regressionPractice guidelinesPatientsTreatment servicesHigh mortalityMortality
2015
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d’Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015, 29: 221-229. PMID: 25426809, PMCID: PMC4284008, DOI: 10.1097/qad.0000000000000540.Peer-Reviewed Original ResearchConceptsMortality rate ratiosCardiovascular diseaseLife expectancyBackground populationNon-AIDS malignanciesAntiretroviral therapy initiationProportion of smokersNorth American cohortSmoking-related mortalityCause of deathMore life yearsAIDS malignanciesAntiretroviral therapyPrevious smokersTherapy initiationSmoking cessationSmoking increasesExcess mortalityAge 35HIVSmokersAmerican cohortSmokingLife yearsHigh mortality
2013
Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States
Collaboration T, del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczer D, Sterling T, Abgrall S, Lampe F, Justice A, Castagna A, Boesecke C, Staehelin C, De Wolf F, Guest J, Mugavero M, Khaykin P, Samji H, Ingle S, Sterne J, Gill M. Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases 2013, 56: 1800-1809. PMID: 23457077, DOI: 10.1093/cid/cit111.Peer-Reviewed Original ResearchConceptsAdjusted mortality hazard ratioAntiretroviral therapyCause mortalityHazard ratioAIDS mortalityHuman immunodeficiency virus-positive subjectsLower mortalityNon-AIDS mortalityAfrican AmericansMortality hazard ratioVirus-positive subjectsAIDS mortality ratesCanadian First Nations peopleFirst Nations peopleCohort studyUS patientsCox regressionEuropean patientsHealthy migrantMortality ratePatientsHigh mortalityMortalityEthnicity/raceDeath rate
2010
Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV
Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, Rimland D, Rodriguez-Barradas MC, Justice AC, Parikh CR. Hepatitis C and the Risk of Kidney Disease and Mortality in Veterans With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 53: 222-226. PMID: 20104121, PMCID: PMC3032564, DOI: 10.1097/qai.0b013e3181b980d4.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHepatitis C virusKidney diseaseMortality rateGlomerular filtration rateAdjusted mortality rateLevels of eGFRVeterans Healthcare AdministrationHepatitis CCoinfected subjectsC virusFiltration rateNational cohortIndependent associationHIVHigh mortalityPoisson regressionMortalityGraduated increaseVeteransCohortHigh rateEGFRDiseaseHealthcare administration
2008
Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies
Harris RJ, Sterne J, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M. Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy 2008, 13: 959-967. PMID: 19195321, PMCID: PMC4507810, DOI: 10.1177/135965350801300802.Peer-Reviewed Original ResearchConceptsHIV type-1-infected patientsMild anemiaAntiretroviral therapyHemoglobin levelsAdjusted hazard ratioMonths of HAARTStart of HAARTActive antiretroviral therapyT-cell countsPrevalence of anemiaProspective cohort studyLong-term prognosisBaseline anemiaAIDS eventsHazard ratioCohort studyPrognostic importancePrognostic valueProspective studyUntreated individualsPatientsAnemiaHigh mortalityHAARTNormal hemoglobin